SCHEMBL1346264

SCHEMBL1346264

FC(F)(F)Oc1ccc(Nc2nnc(-c3sccc3SCc3ccncc3)s2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
ABL1 P00519 2/20 0.38
BCR P11274 2/20 0.38
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
FLT1 P17948 6/20 0.38
KDR P35968 6/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
P2RY1 P47900 1/20 0.37
ALOX5 P09917 1/20 0.35
NAMPT P43490 2/20 0.35
TDO2 P48775 1/20 0.35
PTPN1 P18031 1/20 0.34
METAP2 P50579 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346933 0.84 MEN1 (0.48) ALDH1A1FLT1KDRMEN1KMT2A
SCHEMBL1346368 0.84 LMNA (0.47) ALDH1A1PIK3CDPIK3CAPIK3CBFLT1
SCHEMBL1344699 0.83 KMT2A (0.50) ALDH1A1ABL1BCRPIK3CDPIK3CA
SCHEMBL1345220 0.83 BRAF (0.43) ABL1BCRKMT2AMAPTNPSR1
SCHEMBL1345066 0.81 FLT1 (0.55) FLT1KDR
SCHEMBL1346462 0.80 KDR (0.44) ALDH1A1FLT1KDRMEN1KMT2A
SCHEMBL1344703 0.77 KDR (0.41) ABL1BCRPIK3CDPIK3CAPIK3CB
SCHEMBL1348040 0.76 ALOX5 (0.42) ABL1BCRPIK3CDPIK3CAPIK3CB
SCHEMBL4018411 0.73 L3MBTL1 (0.58) ALDH1A1FLT1KDRSMN1; SMN2NAMPT
SCHEMBL1344961 0.71 KMT2A (0.46) ALDH1A1PIK3CDPIK3CAPIK3CBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US claimed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US claimed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP claimed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY FLT4, VEGFA, FLT1 ALDH1A1 232/4885ABL1 325/4885BCR 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.